Scholar Rock Holding SRRK
NASDAQ SRRK
$55.08 -0.86 (-1.55%)
As of: Sep 4, 2026 · 1:38 PM EDT

Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026)

Scholar Rock Holding (SRRK) posted quarterly Change in Accured Expenses of $4.7 million for Q1 2026, up 236.76% year-over-year from $1.4 million in Q1 2025, and up 145.48% quarter-over-quarter from -$10.3 million in Q4 2025.

Analysis

Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $4.7 million for Q1 2026.

  • In Q1 2026, Change in Accured Expenses rose 236.76% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $16.6 million (up 170.27% YoY), while the FY2025 annual figure was $8.5 million, down 19.31% from the prior year.
  • Change in Accured Expenses for Q1 2026 stood at $4.7 million, up from -$10.3 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $16.4 million in Q2 2025, with the low at -$10.3 million in Q4 2025.
  • The 5-year median for Change in Accured Expenses is $1.6 million (2022), against an average of $1.6 million.
  • Peak annual rise in Change in Accured Expenses reached 3230.83% in 2025, while the deepest fall reached 663.35% in 2025.
  • Scholar Rock Holding's Change in Accured Expenses stood at $1.6 million in 2022, then surged by 91.26% to $3.0 million in 2023, then sank by 39.01% to $1.8 million in 2024, then plunged by 663.35% to -$10.3 million in 2025, then jumped by 145.48% to $4.7 million in 2026.
  • Business Quant data shows SRRK's Change in Accured Expenses at $4.7 million in Q1 2026, -$10.3 million in Q4 2025, and $5.8 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn 11.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - 55.78 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 212.44 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 61.62 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 68.82 Mn
10 Scholar Rock Holding 7.19 Bn 7.19 Bn - 10.22 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.22 Mn
Mar 31, 2026 4.68 Mn
Dec 31, 2025 -10.30 Mn
Sep 30, 2025 5.74 Mn
Jun 30, 2025 16.48 Mn
Mar 31, 2025 -3.43 Mn
Dec 31, 2024 1.83 Mn
Sep 30, 2024 7.25 Mn
Jun 30, 2024 493,000.00
Mar 31, 2024 963,000.00
Dec 31, 2023 3.00 Mn
Sep 30, 2023 3.59 Mn
Jun 30, 2023 -925,000.00
Mar 31, 2023 -9.59 Mn
Dec 31, 2022 1.57 Mn
Sep 30, 2022 5.31 Mn
Jun 30, 2022 1.60 Mn
Mar 31, 2022 -1.58 Mn
Dec 31, 2021 -457,000.00
Sep 30, 2021 2.89 Mn